FIBROGEN INC - COMMON

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

09 Dec 2023 17:02:00 By Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2023 Financial Results

06 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2023 Financial Results

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

29 Aug 2023 16:15:00 By Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2023 Financial Results

07 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

26 Jun 2023 07:04:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

07 Jun 2023 06:55:00 By Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Global Healthcare Conference

06 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

18 May 2023 07:30:00 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2023 Financial Results

08 May 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 May 2023 16:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

05 May 2023 07:30:00 By Nasdaq GlobeNewswire

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 May 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2023 Financial Results

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

03 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

27 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

27 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

17 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen to Present at SVB Securities Global Biopharma Conference

02 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

28 Nov 2022 07:00:00 By Nasdaq GlobeNewswire